FDA advisory committee says risks of Novo Nordisk’s once-weekly insulin outweigh benefits in type 1 diabetes patients
An FDA advisory committee on Friday voted not to recommend Novo Nordisk’s once-weekly insulin injection in type 1 diabetes patients.
Novo has pitched its candidate …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
